226 related articles for article (PubMed ID: 35763229)
1. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
[TBL] [Abstract][Full Text] [Related]
2. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR
Pilewskie M; Sevilimedu V; Eroglu I; Le T; Wang R; Morrow M; Braunstein LZ
Ann Surg Oncol; 2022 Oct; 29(10):6267-6273. PubMed ID: 35849294
[TBL] [Abstract][Full Text] [Related]
3. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
Farley C; Bassett R; Meric-Bernstam F; Bedrosian I; Caudle A; DeSnyder S; Hunt K; Kuerer H; Singh P; Sun S; Tamirisa N; Teshome M; Hwang RF
Ann Surg Oncol; 2023 Dec; 30(13):8327-8334. PubMed ID: 37670121
[TBL] [Abstract][Full Text] [Related]
4. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
[TBL] [Abstract][Full Text] [Related]
5. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
Kantor O; Wakeman M; Weiss A; Wong S; Laws A; Grossmith S; Mittendorf EA; King TA
Ann Surg Oncol; 2021 Mar; 28(3):1358-1367. PubMed ID: 32869154
[TBL] [Abstract][Full Text] [Related]
6. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
Williams AD; Ruth K; Shaikh SS; Vasigh M; Pronovost MT; Aggon AA; Porpiglia AS; Bleicher RJ
Cancer; 2024 Apr; 130(7):1052-1060. PubMed ID: 38018862
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
[TBL] [Abstract][Full Text] [Related]
8. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
9. Prediction of additional lymph node involvement in breast cancer patients with positive sentinel lymph nodes.
Pohlodek K; Bozikova S; Meciarova I; Mucha V; Bartova M; Ondrias F
Neoplasma; 2016; 63(3):427-34. PubMed ID: 26925789
[TBL] [Abstract][Full Text] [Related]
10. Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal.
Cebrecos I; Mension E; Alonso I; Castillo H; Sanfeliu E; Vidal-Sicart S; Ganau S; Vidal M; Schettini F
Ann Surg Oncol; 2023 Aug; 30(8):4657-4668. PubMed ID: 36809608
[TBL] [Abstract][Full Text] [Related]
11. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
[TBL] [Abstract][Full Text] [Related]
12. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
Boughey JC; Yu H; Dugan CL; Piltin MA; Postlewait L; Son JD; Edmiston KK; Godellas CV; Lee MC; Carr MJ; Tonneson JE; Crown A; Lancaster RB; Woriax HE; Ewing CA; Chau HS; Patterson AK; Wong JM; Alvarado MD; Yang RL; Chan TW; Sheade JB; Ahrendt GM; Larson KE; Switalla K; Tuttle TM; Tchou JC; Rao R; Tamirisa N; Singh P; Gould RE; Terando A; Sauder C; Hewitt K; Chiba A; Esserman LJ; Mukhtar RA
Ann Surg Oncol; 2023 Oct; 30(11):6401-6410. PubMed ID: 37380911
[TBL] [Abstract][Full Text] [Related]
13. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
15. Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes.
Schwieger L; Postlewait LM; Subhedar PD; Geng F; Liu Y; Gillespie T; Arciero CA
J Surg Oncol; 2024 Mar; 129(3):468-480. PubMed ID: 37955191
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
17. Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC).
Rocco N; Ghilli M; Curcio A; Bortul M; Burlizzi S; Cabula C; Cabula R; Ferrari A; Folli S; Fortunato L; Frittelli P; Gentilini O; Grendele S; Grassi MM; Grossi S; Magnoni F; Murgo R; Palli D; Rovera F; Sanguinetti A; Taffurelli M; Tazzioli G; Terribile DA; Caruso F; Galimberti V
Eur J Surg Oncol; 2024 Feb; 50(2):107954. PubMed ID: 38217946
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
19. The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E
Breast Cancer; 2022 Mar; 29(2):209-215. PubMed ID: 34591289
[TBL] [Abstract][Full Text] [Related]
20. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
